Although the inspiration for BPC-157 comes from a naturally occurring "Body Protection Compound" (BPC) found in human gastric juice, the active peptide used in research and commercial products is a laboratory-made sequence
doi:10.1002/poc.861 Caffieri S, Miolo G, Seraglia R et al (2007) Photoaddition of fluphenazine to nucleophiles in peptides and proteins
1mL gives 5mg/mL of each (10mg/mL total)
The FDA has identified concerns involving: Potential immunogenicity Peptide-related impurities Limited safety information for proposed routes of administration Insufficient information to determine whether compounded BPC-157 may cause harm in humans This does not prove that every patient who receives BPC-157 will experience a serious adverse event
Both chemical sensitivity and MTHFR challenges stem from the same fundamental issue: cellular processing capacity
In the endosome it blocks entry of viral RNA (19) by not allowing the endosome pH to acidify, thereby preventing the acidic-pH-dependent conformational change required by the coronavirus spike protein to fuse with the endosome membrane (25, 26))